Shareholders of Corteva (NYSE: CTVA) as of September 24 will receive one share of Vylor for every Corteva share they own. The distribution is scheduled for October 1, and Vylor will trade on the New York Stock Exchange under VYLR.
Seven years after Corteva was spun from DowDuPont, it is now producing a spinoff of its own.
Vylor Spinoff Dates and Terms
- Parent: Corteva Inc. (NYSE: CTVA)
- Spinoff: Vylor Inc.
- Ticker: VYLR
- Record date: September 24, 2026
- Distribution date: October 1, 2026
- Distribution ratio: 1 VYLR share for every 1 CTVA share
Vylor is expected to begin when-issued trading on September 25 under VYLR WI. Regular-way trading under VYLR is expected to begin October 1.
Corteva will also have an ex-distribution market under CTVA WI during the when-issued period. Shares trading there will represent post-spinoff Corteva without the right to receive Vylor.
Corteva’s announcement is available here.
Corteva Was a Spinoff Too
Back in 2019, we followed Corteva from its birth out of the sprawling DowDuPont breakup. DowDuPont separated into Dow, DuPont and Corteva, with Corteva containing the combined agriculture businesses of Dow and DuPont.
When the Corteva separation was completed, we wrote about the end of that process here.
The combination of seeds and crop protection inside Corteva is now being partially reversed.
We covered reports of the proposed breakup last September, when Corteva was still considering how to divide the businesses. At the time, the market was focused on the possibility of separating pesticides from seeds. You can read that earlier coverage here.
The final structure puts the seed and advanced-genetics business into Vylor, while Corteva retains crop protection.
Vylor Gets Seeds and Genetics
Vylor will contain Corteva’s seed business, including Pioneer, along with its advanced genetics and related technology platforms.
The remaining Corteva will be a more focused crop-protection company.
This is a meaningful separation rather than the disposal of a small division. The seed business represents a large portion of current Corteva, which means both companies should emerge as substantial standalone businesses.
For investors, the important question is no longer whether the transaction will happen. It is how the market values Vylor relative to the post-spinoff Corteva.
Vylor Is Starting With $1.1 Billion of New Debt
One important part of that valuation is already visible.
Vylor issued $1.1 billion of senior notes in August: $550 million of 5.125% notes due 2031 and $550 million of 5.625% notes due 2036.
Part of the proceeds is intended to fund a cash distribution to Corteva in connection with the separation.
That means Vylor will not simply emerge with the operating assets of the seed business. It will also carry debt raised as part of the transaction.
That debt needs to be included when comparing Vylor’s eventual market capitalization with the value of the business. A valuation based only on equity value would overstate what shareholders are receiving.
The Next Useful Numbers Arrive September 15
Corteva is holding separate investor presentations for the two companies on September 15.
Vylor is scheduled to present at 9:00 a.m. Eastern, followed by the future Corteva at 1:00 p.m.
Those presentations should provide more useful standalone information on earnings, margins, capital allocation and financial targets. We will be looking particularly closely at debt, free cash flow and the different growth profiles of seeds and crop protection.
The next major valuation signal comes September 25, when VYLR WI is expected to begin trading. That will give investors an actual market price for the seed business before the October 1 distribution.
What Happens Next
- September 15: Vylor and Corteva investor presentations
- September 24: Record date
- September 25: Expected start of VYLR WI and CTVA WI trading
- October 1: Vylor distribution and regular-way VYLR trading
We will revisit the transaction after the investor presentations and again once Vylor begins when-issued trading. At that point, we should have enough information to start comparing the market’s standalone valuations of Vylor and Corteva.